ArticleJournal of psychopharmacology (Oxford, England)2022
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.
Article in Journal of psychopharmacology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review.Frontiers in psychiatry · 2026Pooled it
- A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.Nature medicine · 2026Trial
- Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing.Psychopharmacology · 2025Trial
- Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Psychedelics and the 'inner healer': Myth or mechanism?Journal of psychopharmacology (Oxford, England) · 2024Trial
- Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder.European journal of psychotraumatology · 2024Trial
- Trial
- LSD reconfigures cortical dynamics through faster brain rhythms and increased fractal dimension.Communications biology · 2026Article
- The entropic brain today.Brain : a journal of neurology · 2026Review
- Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat.Journal of psychopharmacology (Oxford, England) · 2026Article
- Human brain changes after first psilocybin use.Nature communications · 2026Article
- Prevalence, types, and demographic characteristics associated with major life changes following psychedelic use.Scientific reports · 2026Article
- On the meaning of "plasticity" in neuroscience and mental health research and its relation to the action of psychedelic therapy.Frontiers in neuroscience · 2026Article
- Illuminating consciousness.Frontiers in psychology · 2026Review
- Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic framework.Frontiers in psychiatry · 2026Article
- An exploratory study of breathwork-induced altered states of consciousness in experienced practitioners: the airways to alteration (A2A) trial.Frontiers in psychology · 2026Article
- The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.Brain and behavior · 2025Review
- The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample.Biological psychiatry global open science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAs their name suggests, 'psychedelic' (mind-revealing) compounds are thought to catalyse processes of psychological insight; however, few satisfactory scales exist to sample this. This study sought to develop a new scale to measure psychological insight
methodsThe PIS is a six- to seven-item questionnaire that enquires about psychological insight
resultsPrincipal components analysis of PIS scores revealed a principal component explaining 73.57% of the variance, which displayed high internal consistency at multiple timepoints throughout the study (average Cronbach's α = 0.94). Criterion validity was confirmed using the global psychedelic survey study, and convergent validity was confirmed via the Therapeutic-Realizations Scale. Furthermore, PIS scores significantly mediated the relationship between emotional breakthrough and long-term well-being.
conclusionThe PIS is complementary to current subjective measures used in psychedelic studies, most of which are completed in relation to the acute experience. Insight - as measured by the PIS - was found to be a key mediator of long-term psychological outcomes following a psychedelic experience. Future research may investigate how insight varies throughout a psychedelic process, its underlying neurobiology and how it impacts behaviour and mental health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.